▎ 摘　　要

NOVELTY - Preparing mesenchymal-like stem cells comprises: preparing human pluripotent stem cells cultured to passage less than or equal to 70 after establishment of cell lines; inducing differentiation of the human pluripotent stem cells to produce embryoid bodies and selecting cystic embryoid bodies; loading the cystic embryoid bodies on a cell-permeable three-dimensional (3D) culture unit; culturing the cystic embryoid bodies under conditions sufficient to induce differentiation into mesenchymal-like stem cells; allowing the stem cells to pass through the cell-permeable 3D culture unit and form monolayer-shaped cell clusters; and isolating the monolayer-shaped cell clusters, uniformizing the longitudinal and transverse sizes of the monolayer-shaped cell clusters to 100-500 g, and culturing the mesenchymal-like stem cells, where the stem cells have anti-inflammatory efficacy and immunosuppression, and express cluster of differentiation 90 (CD90) and sex determining region Y-box 2 (SOX2) at a level greater than or equal to 95%. USE - The method is useful for mesenchymal-like stem cells for preventing or treating multiple sclerosis, systemic sclerosis, acute myocardial infarction, chronicmyocardial infarction, chronic lung disease, acute lung disease, Crohn's disease, fecalin continence, graft versus host disease, lower extremity ischemia disease, Burger's disease, foot ulcer, lupus, rheumatoid arthritis, acute and chronic pyelitis, inflammatory cystitis, interstitial cystitis, underactive bladder, overactive bladder, frozen shoulder, rotator cuff injury and rupture, musculoskeletal injury caused by various movements, knee cartilage injury, tinnitus, atopic dermatitis, psoriasis, skin damage from burns, skin damage from ultraviolet light, and inflammatory and immune system diseases including retinopathy, ischemic dementia, Alzheimer's dementia, spinal cord injury, Parkinson's disease, and CNS disease (claimed). No biological data given. ADVANTAGE - The method provides the mesenchymal-like stem cells: which are proved to be genetically stable; effectively control pluripotency of embryonic stem cells; is cost efficient; and improves immunosuppression anti-inflammatory efficacy and pluripotency retention. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) mesenchymal-like stem cells derived from human pluripotent stem cells express matrix metalloproteinase-1 (MMP- 1) protein and hepatocyte growth factor (HGF) protein at a higher level than bone marrow-derived mesenchymal stem cells express MMP-1 protein and HGF protein, express CD95 at a lower level than the bone marrow-derived mesenchymal stem cells expressCD95,and express CD90and SOX2 at a level of greater than or equal to 95%; (2) composition comprising the mesenchymal-like stem, where the composition comprises a cellular therapeutic composition, a cellular gene therapeutic composition, a tissue engineering therapeutic composition, an anti-inflammatory therapeutic composition, an immune therapeutic composition, and a composition for preventing or treating cancer; (3) a transporter comprising the mesenchymal-like stem cells, where the transporter carries a composition; (4) a compositionfor preventing or treating of a disease comprising an active ingredient or exosomes secreted from the mesenchymal-like stem cells; and (5) a cosmetic composition comprising an active ingredient or exosomes secreted from the mesenchymal-like stem cells.